Daily phosphodiesterase type 5 inhibitor therapy: a new treatment option for prostatitis/prostatodynia?

被引：6
作者：
Kirby, Roger S. [1 ]
Carson, Culley, III [3 ]
Dasgupta, Prokar [1 ,2 ]
机构：
[1] Kings Coll London, Guys Hosp, Prostate Ctr, London WC2R 2LS, England
[2] Kings Coll London, Guys Hosp, Dept Urol, London WC2R 2LS, England
[3] Univ N Carolina, Dept Urol, Chapel Hill, NC USA
来源：
BJU INTERNATIONAL | 2014年 / 113卷 / 05期
关键词：
treatment for prostatitis; tadalafil; 5; mg; pelvic pain; prostatitis; ERECTILE DYSFUNCTION; TADALAFIL; PROSTATITIS; MECHANISM; SYMPTOMS; LUTS; BPH;
D O I：
10.1111/bju.12681
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：694 / 695
页数：2
相关论文
共 50 条
  • [41] Phosphodiesterase type 5 (PDE5) inhibitors for the treatment of erectile dysfunction
    Dorsey, Philip
    Keel, Christopher
    Klavens, Meghan
    Hellstrom, Wayne J. G.
    EXPERT OPINION ON PHARMACOTHERAPY, 2010, 11 (07) : 1109 - 1122
  • [42] The role of pharmacokinetics and pharmacodynamics in phosphodiesterase-5 inhibitor therapy
    Mehrotra, N.
    Gupta, M.
    Kovar, A.
    Meibohm, B.
    INTERNATIONAL JOURNAL OF IMPOTENCE RESEARCH, 2007, 19 (03) : 253 - 264
  • [43] The role of pharmacokinetics and pharmacodynamics in phosphodiesterase-5 inhibitor therapy
    N Mehrotra
    M Gupta
    A Kovar
    B Meibohm
    International Journal of Impotence Research, 2007, 19 : 253 - 264
  • [44] The efficacy and safety of udenafil, a new selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction
    Paick, Jae-Seung
    Kim, Sae Woong
    Yang, Dae Yeol
    Kim, Ja Jong
    Lee, Sung Won
    Ahn, Tai Young
    Choi, Hyung Ki
    Suh, Jun-Kyu
    Kim, Sae Chul
    JOURNAL OF SEXUAL MEDICINE, 2008, 5 (04) : 946 - 953
  • [45] Phosphodiesterase 5 inhibitor suppresses prostate weight increase in type 2 diabetic rats
    Kobayashi, Hisato
    Zha, Xinmin
    Nagase, Keiko
    Inamura, So
    Taga, Minekatsu
    Aoki, Yoshitaka
    Ito, Hideaki
    Yokoyama, Osamu
    LIFE SCIENCES, 2022, 298
  • [46] Daily use of phosphodiesterase type 5 inhibitors as prevention for recurrent priapism
    Nardozza Junior, Archimedes
    Cabrini, Marcelo Rodrigues
    REVISTA DA ASSOCIACAO MEDICA BRASILEIRA, 2017, 63 (08): : 689 - 692
  • [47] An update on pharmacological treatment of erectile dysfunction with phosphodiesterase type 5 inhibitors
    Bruzziches, Roberto
    Francomano, Davide
    Gareri, Pietro
    Lenzi, Andrea
    Aversa, Antonio
    EXPERT OPINION ON PHARMACOTHERAPY, 2013, 14 (10) : 1333 - 1344
  • [48] A Return to Normal Erectile Function with Tadalafil Once Daily after an Incomplete Response to As- Needed PDE5 Inhibitor Therapy
    Kim, Edward D.
    Seftel, Allen D.
    Goldfischer, Evan R.
    Ni, Xiao
    Burns, Patrick R.
    JOURNAL OF SEXUAL MEDICINE, 2014, 11 (03) : 820 - 830
  • [49] Antidepressant-like effect of tadalafil, a phosphodiesterase type 5 inhibitor, in the forced swim test: Dose and duration of treatment dependence
    K. V. Otari
    C. D. Upasani
    Neurochemical Journal, 2015, 9 : 306 - 310
  • [50] Efficacy of tadalafil in men with erectile dysfunction naive to phosphodiesterase 5 inhibitor therapy compared with prior responders to sildenafil citrate
    Broderick, Gregory A.
    Donatucci, Craig F.
    Hatzichristou, Dimitrios
    Torres, Luiz O.
    Valiquette, Luc
    Zhao, Yanli
    Loughney, Kate
    Sides, Gregory D.
    Ahuja, Sanjeev
    JOURNAL OF SEXUAL MEDICINE, 2006, 3 (04) : 668 - 675
12345